Their findings revealed that highly aggressive tumors, characterized by high differentiation, hormone receptor negativity (ER and/or PR), and rapid proliferation (high Ki-67), exhibited increased cellular uptake and phosphorylation of FDG (60), and these kinetic parameters can be used to characterize residual lesions following neoadjuvant therapy in locally advanced BC because they less dependent on pre-treatment FDG uptake as static parameters. Here, NR4A1 is linked to breast cancer.